Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

SAVA ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of October 26, 2021 in the Class Action Filed on Behalf of Cassava Sciences, Inc. Limited Shareholders

SAVA

New York, New York--(Newsfile Corp. - September 10, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ: SAVA) alleging that the Company violated federal securities laws.

Class Period: February 2, 2021 and August 24, 2021
Lead Plaintiff Deadline: October 26, 2021
No obligation or cost to you.

Learn more about your recoverable losses in SAVA:
https://www.kleinstocklaw.com/pslra-1/cassava-sciences-inc-loss-submission-form?id=19494&from=5

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7092/96161_276951_logo.jpg

Cassava Sciences, Inc. NEWS - SAVA NEWS

CLASS ACTION CASE DETAILS: The filed complaint alleges that Cassava Sciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO YOU AS A SHAREHOLDER: If you have suffered a loss in Cassava you have until October 26, 2021 to petition the court for lead plaintiff status. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you purchased Cassava securities during the relevant period, you may be entitled to compensation without payment of any out-of-pocket fees.

HOW TO PROTECT YOUR FINANCIAL INTERESTS: For additional information about the SAVA lawsuit, please contact J. Klein, Esq. by telephone at 212-616-4899 or click this link.

ABOUT KLEIN LAW FIRM
J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. The Klein Law Firm is a boutique litigation firm with experience in a wide range of areas including securities law, corporate finance and commercial litigation. Since 2011, our experienced attorneys have achieved superior results for our clients with a personalized focus. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/96161



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today